TRANCOPAL
LOE ApproachingNDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANCOPAL is an oral small-molecule tablet approved in 1960 by Sanofi with an unknown mechanism of action and indication profile. Limited clinical data is available for this legacy product, which may reflect its age and historical approval pathway.
LOE Approaching
As LOE approaches, the brand team is likely in maintenance or wind-down mode with minimal growth investment; commercial headcount may be consolidating.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRANCOPAL is a legacy product with zero linked job openings and approaching loss of exclusivity, making it a low-opportunity assignment for career growth. Positions on this brand are typically defensive or administrative, focused on margin protection rather than expansion.
Brand ManagerField Sales
Worked on TRANCOPAL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.